Objective: With the discovery that familial phaeochromocytoma and paraganglioma syndrome can be caused by mutations in each subunit of the succinate dehydrogenase enzyme (SDH), has come the recognition that mutations in the individual subunits have their own distinct natural histories. Increased genetic screening is leading to the identification of increasing numbers of, mostly asymptomatic, gene mutation carriers and the implementation of screening strategies for these individuals. Yet there is, to date, no international consensus regarding screening strategies for asymptomatic carriers.
| INTRODUC TI ON
Mutations in the genes that encode the subunits of the succinate dehydrogenase (SDH) enzyme were first associated with familial phaeochromocytoma and paraganglioma (PPGL) predisposition in 2000. [1] [2] [3] Initially, mutations in SDHD were described, closely followed by mutations in SDHC 4 and SDHB. 5 More recently, germline mutations in SDHA 6 and the flavoprotein SDHAF2 7 have also been associated with familial PPGL disease.
With more widespread access to genetic testing, an increasing number of apparently sporadic PPGLs are now being identified as familial (current estimates suggest 40%-50%). [8] [9] [10] Cascade genetic screening of relatives is, in turn, leading to the identification of increasing numbers of gene mutation carriers, the vast majority of whom are asymptomatic. These genetic advances open up the potential for direct clinical benefit in as many as half of people destined to develop PPGL disease. To realize this benefit, it will be necessary to formulate screening programmes that identify PPGL at an early stage, prior to the development of symptoms and/or metastatic spread. However, there is no international consensus regarding screening strategies for asymptomatic carriers. Important barriers to the development of consensus guidelines for screening include uncertainties, for each subunit, regarding the site, rate of growth and potential for metastasis of PPGL; and (particularly for SDHB) a growing realization, as more asymptomatic carriers are identified, that previous prevalence estimates were erroneously high. Together with the resource/health economic considerations that arise from intensive radiological screening programmes for increasing numbers of often asymptomatic individuals, these issues have led to markedly different strategies being employed between centres, both nationally and internationally.
Recent guidelines 11 combine evidence and expert opinion to direct the appropriate course of management in the ongoing care and monitoring for recurrence or metastatic disease of patients with PPGL disease and have produced workable algorithms to identify the most likely underlying causative gene in the index case. For many clinicians, however, it is defining the modality and frequency of imaging for the gene carriers identified via cascade screening that is, paradoxically, more difficult.
It has required more than a decade of accumulated clinical experience and follow-up of SDH-related PPGL to provide sufficient understanding of the natural history to now allow workable guidelines and algorithms to be formulated. Mutations in each different SDH subunit are surprisingly different in terms of inheritance, penetrance, tumour location and risk of malignant transformation. Consequently, there is also a growing recognition that previous screening strategies may now be inappropriate. In parallel with an increased understanding of the genetic basis of familial PPGL disease, there have been significant advances in the diagnostic imaging techniques for the localization of primary and metastatic disease. As the estimates of penetrance and risk of metastatic spread are revised down, it is the balance of the benefits of radiological surveillance, and the consequences for patient anxiety, resource allocation and (where utilized) the effects of ionizing radiation on tumour formation 12 that has become the clinical focus of discussion. The clinical use of biomarkers for screening is an exciting prospect for the future.
Most centres have implemented screening strategies for SDH mutation carriers independent of the subunit affected, but it would seem reasonable, with our current cumulative knowledge, to consider starting to define more sub-unit focused strategies.
In this review, we have analysed all the data in the literature on phenotype and malignancy risks of individual SDH subunits in addition to the accumulated, published experience of screening asymptomatic SDH mutation carriers in order to inform the development of screening protocols. Using this data, we suggest surveillance screening of asymptomatic carriers can be tailored to the underlying SDH subunit.
We describe the issues relating to modality, frequency and age of commencing screening that have, to date, limited the formation of a consensus with regards to the development of screening programmes.
| SURVEILL AN CE PROG R AMME S
Once an SDH mutation carrier has been identified, it is universally accepted that inclusion in a screening programme is appropriate and that such a programme should include a comprehensive clinical evaluation with biochemical testing for abnormal catecholamine production (plasma and/or urine metanephrines). However, a significant proportion of SDH-associated PPGLs remain clinically and biochemically silent for a prolonged period due to lower tumoural production of catecholamines, [13] [14] [15] and the majority of parasympathetic PGLs are non-secretory. 16 In recent years, there has been increasing evidence that size of tumour correlates with malignant potential, 14, 17, 18 and the aim of screening is to identify tumours at early stages. If novel, more sensitive and specific biomarkers are discovered, we recognize that the role of imaging will diminish. However, it seems clear for now, that imaging must play the central role in screening asymptomatic SDH gene carriers.
A number of studies and guidelines have suggested potential surveillance programmes for managing SDH gene mutation carriers, reviewed in detail elsewhere (Supporting Information Table S1 ).
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Most of these, however, do not differentiate between the followup of asymptomatic carriers and those that have (or have previously had) tumours; and very few suggest "tailor-made" surveillance imaging programmes based on specific SDH-subunit gene mutations.
In order to develop a "bespoke" surveillance strategy for SDH mutation carriers, it is first necessary to understand and catalogue differences in the natural history of diseases associated with mutations in the different SDH subunits. As an initial step, we have combined informative data from multiple published cohorts in order to guide the development of potential surveillance protocols for individual SDH subunits. There are inherent difficulties associated with gathering and reporting clinical outcomes in cohorts of SDH mutation carriers and, by implication, limitations to how confidently conclusions can be drawn from attempts to draw together data derived from different centres. We also acknowledge that there is the possibility of overlap in the clinical cohorts analysed (eg, with groups reporting outcomes on growing cohorts of patients), which we have tried to minimize.
We present the combined data for each subunit in order of the most commonly identified subunit mutations; recognizing that patients affected by mutations in SDHB and SDHD make up the majority of individuals in most centres.
| SDHB

| Penetrance
Mutations in the SDHB gene account for 10% of cases of all PPGLs and approximately one quarter of familial disease. 8, 20, 21 To date, a total of 287 unique mutation variants have been reported in the SDH database. 22 The importance of surveillance screening in asymptomatic relatives is highlighted when analysing studies that separate out the asymptomatic carriers/relatives from the index cases (Table 1) .
These combined cohorts provide data on 1341 asymptomatic SDHB carriers and demonstrate a tumour detection rate of 15.4% (207 asymptomatic carriers with PPGLs identified on screening), when index cases are excluded (individual studies report a tumour detection rate ranging from 3.5% to 35%). [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Penetrance estimates have fallen over time as more disease-free asymptomatic carriers are identified. Table 2 shows the changes in estimates in age-related penetrance, for all SDHB carriers (Table 2a) and then specifically for asymptomatic carriers only (Table 2b) . More recent studies suggest figures as low as 22%-26% at age 60 years 32,33 and 30%-44% at age 80 years 33, 35 and some authors suggest as little as 1%-3% at <20 years 29, 32, 35 in the asymptomatic carrier population, with recent suggested significant differences in prevalence between male and female carriers. 32 The most recent analysis 33 is based only on clinically apparent disease at the time of genetic testing, so these figures will underestimate the true penetrance, as they do not factor in asymptomatic disease.
| Phenotype
A recent review 36 concluded that, although the most common site of paraganglioma (PGL) disease in SDHB mutation carriers is Figure 1 and Supporting Information Table S2 ). We provide two sets of data for patients that develop a tumour (Supporting Information Table S2 ); firstly, the percentage chance of this being at any given site ( Figure 1A ). In combination with prevalence data, this enables one to define the clinical risk to the patient. Secondly, the percentage of tumours that occur at each site, to help define which sites warrant surveillance imaging.
Interestingly, although it is widely recognized that the most likely site to develop a PGL is extra-adrenal abdominal, the combined data suggest the risk of developing HNPGL is just as high. The oldest patient identified was 93 years with a HNPGL identified on surveillance imaging. 30 Although the prevalence is much lower, PPGLs occur in the paediatric population, and there are some data to suggest that they are much more likely to become malignant, with TA B L E 2 Reported PPGL penetrance figures for SDHB mutation carriers from published cohorts (a) shows age-related lifetime penetrance of PPGL calculated for all SDHB mutations carriers (includes both index cases and asymptomatic carriers), in chronological order (b) shows age-related lifetime penetrance of PPGL for SDHB asymptomatic carriers/relatives/non probands only, in chronological order Although more recently these same authors 33 have extended their cohort and report no difference in age-related risks of PPGL between missense and truncating mutations, they did suggest a non-significant trend towards higher overall penetrance in mutation carriers with the mutation predicted to cause the most severe protein instability (p.Ile127Ser). They suggested that there was a higher risk of HNPGL specifically with the p.Gly96Ser missense mutation (causing abnormal splicing) and that there was a nonsignificant trend towards an increased risk of malignancy at age 60 years when mutations occurred in the first 300 nucleotides than with more 3' mutations. Recently, Jochmanova et al 32 have we have calculated malignancy risk by tumour location. This included a total of 344 tumours, where 95 cases were associated with malignancy (27.6%), in keeping with previous reports.
Probably of more clinical relevance is to look at the malignancy risk as a percentage of the total tumours that occurred at each site ( Figure 2A and Supporting Information Table S2 ). These data actually suggest that the risk of malignant transformation is the same for both PCC and extra-adrenal abdominal PGLs in SDHB carriers.
The notable exception here is bladder PGLs; although the series was small, concern has been raised about their substantial malignant potential. 50, 51 Another key finding is that the risk of malignant transformation of HNPGL in SDHB carriers appears to be lower compared to PPGLs that develop at other sites. Clearly, these data should be interpreted with caution as the numbers of tumours at some sites are small. 
| Other associated tumours
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The predominant clinical feature of SDHD mutation carriers is the development of HNPGL, with 85% of carriers developing tumours at these sites. 36 PCC and extra-adrenal sympathetic PGLs are reported to occur less frequently in 10%-25% and 20%-25% of carriers, respectively. 27 Multifocal disease is much more common in SDHD carriers, with estimates that 55%-60% of carriers develop multiple tumours. 27 The importance of surveillance screening in asymptomatic relatives is again highlighted when analysing studies that separate out the asymptomatic carriers/relatives from the index cases (Table 1) . These combined cohorts provide data on 257 asymp- 
| Phenotype
We have used published clinical data to calculate the risk of tumour formation based on disease site ( Figure 1B and Supporting Information 
| Malignancy risks
It is recognized that PPGLs occurring in SDHD carriers run a more benign course. A detailed systemic review and meta-analysis has been previously undertaken 48 and included 10 cohorts of SDHD mutation carriers with malignant disease. The pooled risk for incidence of malignancy was 8% for all SDHD mutations carriers. Malignancy has been reported across a spectrum of SDHD mutations.
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F I G U R E 2 A $ , Risk of malignancy in SDHB mutation carriers of different PPGL based on site of occurrence.
The graph shows the risk of malignancy for each PPGL tumour location in SDHB mutation carriers, as a percentage of the total number PPGLs occurring at each site of disease. Total number of tumours is normalized to 100% and the actual number of tumours included is given as an "n" number at the base of each column. These figures are derived from a total of 95 malignant PPGLs (with a malignancy rate of 27.6%). We have divided pelvic PGL into those that arise in the bladder and those that arise outside the bladder as, from the reported data, it is possible that the bladder PGLs have a particularly high malignancy rate which is worthy of note. B $$ , Risk of malignancy in SDHD mutation carriers of different PPGL based on site of occurrence. The graph shows the risk of malignancy for each PPGL tumour location in SDHD mutation carriers, as a percentage of the total number PPGLs occurring at each site of disease. Total number of tumours is normalized to 100% and the actual number of tumours included is given as an "n" number at the base of each column. These figures are derived from a total of 28 malignant PPGLs (with a malignancy rate of 6.7% Figure 2B and Supporting Information Table S3 ). This included a total of 413 tumours, where 28 cases were associated with malignancy (6.7%).
Although still relatively low at <10%, the risk of malignant transformation was highest in HNPGLs (7.5%) and similar for all the sympathetic sites (3.8%-5.2%). 
| Other associated tumours
| SDHC
| Penetrance
Mutations in SDHC gene account for 1%-2% of cases of all PPGLs. 8, 20 To date, a total of 83 unique mutation variants have been reported in the SDH database. 22 Andrews et al 33 estimated risk of disease at age 60 years at 25% in mutation-positive non-probands. 
| Phenotype
| Other associated tumours
Two cases of pituitary adenoma occurring in individuals with SDHC mutations have been described with macroprolactinoma and HNPGL, but no tissue was available for LoH studies to prove pathogenicity. 63 Eight RCC 52, 55, 87 and multiple GISTs [88] [89] [90] have been reported in patients harbouring SDHC mutations.
| SDHA
| Penetrance
Mutations in the SDHA gene were first associated with autosomal recessive inheritance of the mitochondrial disease Leigh syndrome (juvenile encephalopathy) 91 and more recently with severe neurological dysfunction and cardiomyopathy. 92 As an au- 
| Phenotype
Several recent case reports or small cohorts of patients carrying SDHA mutations have been published. [94] [95] [96] [97] [98] [99] [100] [101] To date, the total number of cases reported is 93 with 41 different mutations. (28) 2% (1) Abdo/Pelvic PGL 29% (27) 11% (14) 0 HNPGL 48.4% (45) 69.3% (88) 94% (46) Thoracic PGL 3.2% (3) 4.7% (6) 2% (1) Intra-thyroidal PGL 3.2% (3) 0 2% (1) No. of patients with multiple PPGLs 8.6% (8) 36% (46) 53% (26) No. of patients with malignant PPGLs 9.6% (9) 5.5% (7) 0 
| Other associated tumours
GIST and pituitary adenoma have been described in eight 95, 100, 101 and four patients, 62, 101 respectively, carrying germline SDHA mutations with PPGL disease, and metastatic GIST has been reported.
95
SDH-deficient GIST are most commonly associated with germline mutations in SDHA, accounting for 30% of SDH-deficient GISTs with 20% due to SDHB, D and C germline mutations. 90 Interestingly, approximately 50% of SDH-deficient GIST are due to somatic mutations and SDH-deficient GIST are now recognized as a unique class of GIST.
90,103
| SDHAF2
Very few cases of PPGL associated with mutations in SDHAF2 have been described. 7,100,104-106 The association was first described in 
| MODALIT Y AND FREQUEN C Y OF IMAG ING SDH MUTATI ON C ARRIER S (CURRENT PR AC TI CE)
Very few studies separate out the different SDH subunits in terms of surveillance screening. Most centres use SDHB mutation carriers as the basis of their screening programmes, as this group make up the bulk of the affected population in the majority of centres. Table 1 in the supplementary data summarizes the different suggested surveillance programmes that have been reported and is an updated table published previously.
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Recommendations for screening have often been based on studies looking at sensitivity and specificity of different imaging modalities in comparison to each other 23, [107] [108] [109] and some recommendations regarding specific imaging modalities and frequencies, appropriate when there was less knowledge and an assumed higher penetrance, would no longer be considered valid by the recommending centres.
An understanding of the different sensitivities and specificities is important but must be interpreted in the setting of the clinical goal of surveillance in a particular cohort. The goal of a surveillance programme is to detect all tumours before they cause morbidity or undergo malignant transformation, thereby allowing therapeutic intervention at the correct time (which may be after a period of more focused surveillance (Supporting Information   Table S1 , Table S2, Table S3 Clinical priority is to define when and how to intervene to minimize patient morbidity, given the growing consensus that fractionated or stereotactic radiation is highly effective and avoids the inevitable cranial nerve morbidity of surgical resection and the recognised slow growth rate HNPGLs 64, 67, 131, 132 When an asymptomatic tumour is identified, we would recommend more frequent surveillance imaging to assess growth rates so that timing of intervention can be planned. For HNPGLs, the frequency of scanning and timing of intervention should also take into account the site, recognising the reported increased aggressiveness and malignancy rates of jugular and vagal PGLs, over carotid body PGLs
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SDHC
As per SDHD recommendations
There is insufficient evidence to define a distinct surveillance strategy for this subtype. SDHC mutations appear to have sites of disease and malignancy rates that are similar to SDHD.
As more data accumulates we would expect the interval of these surveillance scans to increase (relative to SDHB&D) given the lower penetrance of disease
SDHA
As per SDHB recommendations
There is insufficient evidence to define a distinct surveillance strategy for this subtype. The sites of disease are similar to SDHB, however penetrance and malignancy rates are lower.
(Continues) , that imaging surveillance should be with the exclusive use of MRI for all SDH surveillance screening, with radiation modalities reserved for; the further characterization of tumours identified on screening, treatment planning if required and the detection and surveillance of known or potential metastatic disease (e.g. after the excision of a large SDHB-related PPGL where potential metastatic disease is a possibility). In order to maintain maximal sensitivity and specificity with MRI, careful liaison with diagnostic imaging departments is required. This will ensure the correct sequences are performed (covering the relevant at risk sites) and that expertise is accumulated with a limited number of individuals working within a designated group that facilitates two-way feedback, audit and improvement. If resources permit, the published data would suggest that, in line with other screening programmes, 'double reporting' increases the tumour detection rate by 5-10%
SDH subunit Surveillance screening proposals
Rationale
Additional comments
First screen
Subsequent surveillance
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. Although preliminary experience at present, the authors commend the additional use of diffusion-weighted imaging (DWI) sequences which we have found to have a sensitivity of 100% for highlighting SDHB-related tumours. Collaborative work is now required to further define the most appropriate sequences, for example the use of rapid sequencing for whole body imaging including T1, T2
and diffusion weighted images will shorten image acquisition time with less strain on resources, if proven to maintain high sensitivity. It should be emphasized that the level of understanding of the natural history of phenotypes for SDHC and SDHA mutations is substantially less than for SDHB and SDHD (and even less for SDHAF2) and for all subunits, the accumulation of further knowledge, as well as prospective evaluation of any given screening strategy, will enable these strategies to be refined further.
a Given the above figure of 35% of SDHD mutation carriers developing a PCC, any clinical and/or biochemical suspicion should, clearly, prompt earlier abdominal imaging.
TA B L E 5 (Continued)
tumour hypermetabolic activity, rather than PPGL specific metabolism, to increase sensitivity for less differentiated tumours. In-diethylene triamine pentacetic acid-pentetreotide scintigraphy (octreoscan) 11 have been
shown to be less useful in SDHx surveillance imaging.
The Endocrine Society clinical practice guidelines, however,
suggest that CT and nuclear medicine imaging modalities should be reserved for further characterization of detected tumours to avoid ionizing radiation exposure especially as this cohort of patients require recurrent scanning, often from a young age and, by definition, are a group prone to tumour development.
Regular clinical review and biochemical assessment (plasma or 24-hour urine metanephrines) of SDH mutation carriers is universally recommended. However, it is also recognized that with a sensitive imaging surveillance programme, all lesions could be detected before they have a clinical or biochemical correlate. Suggested frequency of imaging surveillance is again highly variable (Supporting Information Table S1 
| CON CLUS ION
The overarching aim of any SDH surveillance programme must be to identify disease at an early stage with small tumour sizes in order to allow intervention at the appropriate time, improve cure rates and limit the chance of malignant transformation. In our opinion, there are now sufficient published clinical data (particularly for SDHB and SDHD) to begin the process of drafting recommendations for surveillance screening which take into account the known epidemiology of each subunit and the goals of screening for each subunit (with future modifications as further data become available). A consensus also needs to be reached with respect to the acceptable "miss rate" and the target detection level which will guide the frequency of scanning (most nationwide screening programmes being set for a detection level of 5%). 128 For completion, in the absence of any consensus guidelines Table 5 outlines a possible MRI based sub-unit specific protocol with goals of screening and the rationale behind the frequency. This is based on our review of the data, recognition of the Endocrine Society guidelines 11, 115 which recommend MRI should be used in patients in whom radiation exposure should be limited (eg, patients with known germline mutations), and our personal experience with MRI in this cohort of patients. We will implement these at our centre until consensus guidelines are published. The subjective nature of these is fully acknowledged. Like many areas of clinical practice, the modality and frequency of screening that individual centres adopt will be dependent on issues such as cost and local expertise. It would be valuable for any surveillance programmes to undergo prospective auditing and validation so that successful programmes can be more widely adopted. Biomarkers will also have an increasing importance in surveillance programmes when they become sensitive and specific enough to identify early disease.
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